the Effect of Dexmedetomidine in Coracoid Approach Brachial Plexus Block

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-12

Study Completion Date

2017-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dexmedetomidine is an α-2 adrenoreceptor agonist and has been extensively used through intravenous infusion，in order to improved the quality of block in regional anesthesia. In this prospective, randomized study, the authors focus on the effect of dexmedetomidine mixed with ropivacaine in coracoid approach brachial plexus block.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexmedetomidine in IVRA

NCT05123170

Regional Anesthesia Morbidity

COMPLETED PHASE4

Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries

NCT07290595

Post Operative Analgesia Bradycardia Hypotension +1 more

RECRUITING PHASE2/PHASE3

Effect of Intravenous Dexmedetomidine Versus Dexamethasone for Management of Repound Pain After Supraclavicular Brachial Plexus Block

NCT06304909

Trauma Injury

NOT_YET_RECRUITING PHASE1

Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial)

NCT02630290

Radius Fractures Ulna Fractures Hand Injuries +2 more

COMPLETED PHASE4

Duration of Analgesia With Dexmedetomidine and Ropivacaine in Brachial Plexus Block

NCT03385967

Analgesia Pain, Acute Peripheral Nerve Block

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Injury of Upper Limb

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group Control

40 ml 0.375% ropivacaine was injected after Locating brachial plexus.

Group Type EXPERIMENTAL

ropivacaine

Intervention Type DRUG

40 ml 0.375% ropivacaine was injected after Locating brachial plexus.

Group Dexmedetomidine

40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.

Group Type EXPERIMENTAL

ropivacaine mixed with dexmedetomidine

Intervention Type DRUG

40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ropivacaine

40 ml 0.375% ropivacaine was injected after Locating brachial plexus.

Intervention Type DRUG

ropivacaine mixed with dexmedetomidine

40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. American Society of Anesthesiologists (ASA) physical status I or II;
2. Aged 18-60 years;
3. The elbow, forearm, wrist or hand surgery

Exclusion Criteria

1. History of allergy to local anesthetics;
2. Coagulation dysfunction, neuromuscular disease or local infection;
3. The operation time is longer than the local anesthetics effective time.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No